Inflammatory Bowel Disease
Test in Focus
Mayo Clinic Laboratories’ IBDP2 serology panel detects for the presence of antibodies against Saccharomyces cerevisiae IgA and IgG, and anti-neutrophil cytoplasmic antibodies (pANCA) to confirm disease presence in patients for whom diagnosis is unclear. In this “Test in Focus” episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
“Ulcerative colitis and Crohn's disease are really clinical diagnoses where the physician takes into account the clinical picture, some imaging studies, and maybe pathology to make a diagnosis,” Dr. Snyder says. “And for most patients, this is enough. Inflammatory bowel disease serology testing can be useful in a small subset of patients to help when it's difficult to differentiate between ulcerative colitis and Crohn's disease.”
Inflammatory bowel disease serology testing at Mayo Clinic Laboratories incorporates measures that improve testing quality and ensure accuracy of test results, Dr. Snyder adds. “We want to make sure that when we provide a result to a patient, the patient can rely on that result, the physician can rely on that result.”
Listen to learn more about how IBDP2 can help distinguish between ulcerative colitis and Crohn’s disease for some patients with IBD.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 1 mL
Katherine Geiersbach, M.D., explains how Mayo Clinic Laboratories' PIK3CA assay informs breast cancer treatment. The assay identifies patients eligible for a certain second-line therapy when initial treatment has failed.
Joseph Maleszewksi, M.D., and Marie-Christine Aubry, M.D., explain how Mayo Clinic Laboratory can provide definitive diagnosis of primary ciliary dyskinesia (PCD). Mayo Clinic's expertise and technology have earned the laboratory's designation as the sole center of excellence for diagnosing this rare respiratory disorder.
Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.